Yury, a 44-year-old melanoma patient from Greece, had undergone years of systemic treatment following his diagnosis of advanced cutaneous melanoma. He received surgery, monoclonal antibody therapy, radiotherapy, and two different immune-combination regimens. Despite these extensive efforts, his disease continued to progress. By May 2025, imaging showed further spread to the liver, peritoneum, hilar region, and peripancreatic areas. Genetic testing revealed an NRAS Q61R mutation, a subtype known to respond poorly to conventional therapies, greatly limiting subsequent treatment options.

After multiple lines of therapy had failed, Yury came to GoBroad Healthcare Group seeking new possibilities. Professor Jun Guo and his team conducted a comprehensive assessment of his condition, treatment history, and molecular profile. Based on this evaluation, they designed a more targeted, personalized treatment plan built around Tunlametinib combined with immunotherapy, aiming to regain disease control by inhibiting the NRAS-MEK pathway.

Just six weeks after treatment initiation, his imaging results showed an encouraging shift. His overall tumor metabolic activity decreased dramatically, several previously active lesions became metabolically inactive, and no new lesions appeared—indicating a partial response.

For a patient with NRAS-mutant melanoma who had already exhausted several immunotherapy options, this represented a highly valuable therapeutic outcome. Yury shared that the confidence he had gradually lost during years of treatment was rekindled at GoBroad, and this therapy restored his belief that his disease could once again become manageable.